Low Prevalence of Hypomagnesemia in Long-term Recipients of Proton Pump Inhibitors in a Managed Care Cohort

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 2, 2016, Pages 317-321

  Sharara, Ala I ^a   Chalhoub, Jean M ^a   Hammoud, Nijmeh ^a   Harb, Ali H ^a   Sarkis, Fayez S ^a   Hamadeh, Ghassan ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Acid suppression; Adverse events; Diuretics; Magnesium; Side effects

Indexed keywords

MAGNESIUM; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC DIARRHEA; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PATIENT CARE; PREVALENCE; CHEMICALLY INDUCED; HEALTH INSURANCE; MAGNESIUM DEFICIENCY; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MAGNESIUM DEFICIENCY; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PREVALENCE; PROTON PUMP INHIBITORS;

EID: 84959016813     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.10.012     Document Type: Article

References (26)

1. Florentin M., Elisaf M.S. Proton pump inhibitor-induced hypomagnesemia: a new challenge. World Journal of Nephrology 2012, 1:151-154.
2. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2057.
3. Valuck R.J., Ruscin J.M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422-428.
4. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
5. Wilhelm S.M., Rjater R.G., Kale-Pradhan P.B. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 2013, 6:443-451.
6. Zipursky J., Macdonald E.M., Hollands S., et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med 2014, 11:e1001736.
7. Sumukadas D., McMurdo M.E., Habicht D. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J Am Geriatr Soc 2012, 60:392-393.
8. Danziger J., William J.H., Scott D.J., et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013, 83:692-699.
9. Epstein M., McGrath S., Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006, 355:1834-1836.
10. Cundy T., Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008, 69:338-341.
11. Mackay J.D., Bladon P.T. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010, 103:387-395.
12. Markovits N., Loebstein R., Halkin H., et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol 2014, 54:889-895.
13. Faulhaber G.A., Ascoli B.M., Lubini A., et al. Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Revista da Associacao Medica Brasileira 2013, 59:276-279.
14. Park C.H., Kim E.H., Roh Y.H., et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PloS One 2014, 9:e112558.
15. Biyik M., Solak Y., Ucar R., et al. Hypomagnesemia among outpatient long-term proton pump inhibitor users. Am J Ther 2014.
16. Schlingmann K.P., Weber S., Peters M., et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002, 31:166-170.
17. Quamme G.A. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol 2008, 24:230-235.
18. Voets T., Nilius B., Hoefs S., et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004, 279:19-25.
19. Costa A., Tejpar S., Prenen H., et al. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Targeted Oncology 2011, 6:227-233.
20. Perazella M.A. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int 2013, 83:553-556.
21. Koulouridis I., Alfayez M., Tighiouart H., et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 2013, 62:730-737.
22. Van Ende C., Van Laecke S., Marechal C., et al. Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. J Nephrol 2014.
23. Gau J.T., Yang Y.X., Chen R., et al. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012, 21:553-559.
24. Luk C.P., Parsons R., Lee Y.P., et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?. Ann Pharmacother 2013, 47:773-780.
25. Lindner G., Funk G.C., Leichtle A.B., et al. Impact of proton pump inhibitor use on magnesium homoeostasis: a cross-sectional study in a tertiary emergency department. Int J Clin Pract 2014, 68:1352-1357.
26. Kim S., Lee H., Park C.H., et al. Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. Am J Ther 2015, 22:14-21.